From the Guidelines
Arni, specifically sacubitril/valsartan, is the recommended treatment for heart failure with reduced ejection fraction (HFrEF) due to its superior efficacy in reducing cardiovascular mortality and heart failure hospitalizations compared to ACE inhibitors, as demonstrated in a large randomized clinical trial and supported by subsequent studies 1. The diagnosis of atrial fibrillation (AF) is not directly related to the use of Arni, but it's essential to establish the diagnosis of AF through electrocardiographic documentation, as recommended by the 2014 AHA/ACC/HRS guideline 1. In the context of heart failure, Arni has been shown to be effective in reducing morbidity and mortality, with a typical starting dose of 49/51 mg twice daily, which can be titrated to a target dose of 97/103 mg twice daily as tolerated. Key considerations when initiating Arni include discontinuing ACE inhibitors at least 36 hours prior to prevent angioedema and monitoring for common side effects such as hypotension, hyperkalemia, cough, dizziness, and renal dysfunction. The dual mechanism of action of Arni, which blocks the harmful effects of angiotensin II and inhibits neprilysin, enhances cardiac function, promotes vasodilation, increases sodium excretion, and reduces cardiac remodeling, making it a valuable treatment option for patients with HFrEF. Overall, the use of Arni in patients with HFrEF has been consistently supported by high-quality evidence, including a large randomized clinical trial and subsequent studies, making it a recommended treatment option for reducing cardiovascular mortality and heart failure hospitalizations 1.
From the Research
Arni Information
- There is no direct information available on "Arni" in the provided studies.
- However, study 2 mentions "ARNI" which stands for Angiotensin Receptor-Neprilysin Inhibitor, a new treatment for heart failure with reduced left ventricular ejection fraction (LVEF).
- The study 2 discusses the use of sacubitril-valsartan, an ARNI, in the management of heart failure, including its initiation, use, and place in the drug management strategy.
Related Studies
- Studies 3, 4, 5, and 6 are related to ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), and its uses, safety, and efficacy.
- These studies do not provide information on "Arni" or "ARNI" directly, but may be relevant for understanding the context of pharmaceutical treatments and their effects on the body.
Key Findings
- Study 2 highlights the importance of ARNI in the management of heart failure with reduced LVEF, and provides guidance on its use and initiation.
- The other studies 3, 4, 5, and 6 provide information on ibuprofen, including its pharmacology, efficacy, safety, and potential side effects, but are not directly related to "Arni" or "ARNI".